SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — May 4, 2017

AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: May 4, 2017 · CIK: 0000946644 · Accession: 0001493152-17-004756

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

May 4, 2017

Author

Director

Form

CORRESP

Company

AIM ImmunoTech Inc. (AIM) (CIK 0000946644)

Letter

Division of Corporation Finance Securities and Exchange Commission F Street, NE Washington, DC 20549 Re: Hemispherx Biopharma, Inc. Registration Statement on Form S-1

Dear Ms. Hayes:

On behalf of Hemispherx Biopharma, Inc. (the “Company”), we file herewith the above referenced registration statement.

Please direct any comments and other communications to the undersigned.

Very
truly yours,
/s/
Richard Feiner

Show Raw Text

CORRESP
1
filename1.htm

        SILVERMAN
        SHIN & BYRNE PLLC

        Wall
        Street Plaza

        22nd
        Floor

        88
        Pine Street

        NEW
        YORK, NY 10005

        212.779.8600

        Facsimile:
        212.779.8858

        __________

        New
        Jersey

        19
        Engle Street

        Tenafly,
        NJ 07670

        (201)
        567-4969

May
4, 2017

Suzanne
Hayes

Assistant
Director

Division
of Corporation Finance

Securities
and Exchange Commission

100
F Street, NE

Washington,
DC 20549

    Re:
    Hemispherx
    Biopharma, Inc.

    Registration
    Statement on Form S-1

Dear
Ms. Hayes:

On
behalf of Hemispherx Biopharma, Inc. (the “Company”), we file herewith the above referenced registration statement.

Please
direct any comments and other communications to the undersigned.

    Very
    truly yours,

    /s/
    Richard Feiner

    Richard
    Feiner

cc:
Hemispherx Biopharma, Inc.

SecProbe.io